arrow_back Back to App

Drug Price Transparency: Mandatory Disclosure of Costs in Consumer Ads.

This Act mandates that direct-to-consumer advertisements for prescription drugs must clearly disclose the Wholesale Acquisition Cost (WAC) for a 30-day supply. This change aims to empower citizens to better estimate their out-of-pocket expenses, particularly those with high-deductible health plans. The goal is to foster informed decision-making and increase price competition in the pharmaceutical market.
Key points
Drug manufacturers must display the Wholesale Acquisition Cost (WAC) for a 30-day supply in all consumer advertisements.
This provides consumers with crucial cost information before receiving a prescription, helping them manage personal finances.
Drugs with a WAC below $35 for a 30-day supply are exempt from this disclosure requirement.
Non-compliance with the new rules may result in civil monetary penalties of up to $100,000 per violation.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1250
Sponsor: Sen. Durbin, Richard J. [D-IL]
Process start date: 2023-04-20
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug-price Transparency for Consumers Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1250.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-04-20.

What are the main provisions?

Key points include:

  • Drug manufacturers must display the Wholesale Acquisition Cost (WAC) for a 30-day supply in all consumer advertisements.
  • This provides consumers with crucial cost information before receiving a prescription, helping them manage personal finances.
  • Drugs with a WAC below $35 for a 30-day supply are exempt from this disclosure requirement.
  • Non-compliance with the new rules may result in civil monetary penalties of up to $100,000 per violation.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Durbin, Richard J. [D-IL].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Economy